2010

MSc Calin Constantin Ciocoiu ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Synthesis and biological evaluation of regulators of peroxisome proliferator-activated receptors

Cand. pharm. Kristin Odlo ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Synthesis and Biological Evaluation of 1,2,3-Triazole Analogues of Combretastatins A-4 and A-1

Cand. pharm. Nina Pettersen Hessvik ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Regulation of lipid and glucose metabolism in skeletal muscle cells: Metabolic switching, mitochondrial function and the roles of LXRs

Cand. pharm. Helle Håkonsen ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Pharmaceutical price control strategies in Norway: Implications for optimal drug use

Cand. pharm. Anne Bee Hegge ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Formulation of a hydrophobic photosensitizer for topical photodynamic therapy. Application of alginate and cyclodextrins

Cand. pharm. Tom Erik Grønhaug ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Pectic polysaccharides with immunomodulating activities from Malian medicinal plants

Cand. pharm. Karoline Fægri ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Adaptive responses in Bacillus cereus group bacteria - microarray comparisons and follow-up studies

Cand. scient. Kirsten Eline Rakkestad ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Studies on Indoor Air Pollution – characterization of phthalates in Norwegian indoor environments, and effects of phthalates and mold on respiratory health

Cand. pharm. Ine Blankenberg Skottheim ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d. (philosophiae doctor): Pharmacokinetics of atorvastatin in special populations – Patients with statin induced myopathy and morbidly obese patients undergoing bariatric surgery